PROZAC by Eli Lilly and Company is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. Approved for depressive episodes associated with bipolar i disorder, the treatment of treatment resistant depression. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
PROZAC (fluoxetine) is an oral solution small-molecule SSRI approved in 1991 for depressive episodes in Bipolar I Disorder and treatment-resistant depression. It works by inhibiting CNS neuronal uptake of serotonin, modulating mood and emotional regulation. The drug remains a foundational antidepressant despite its approaching loss of exclusivity.
With LOE approaching and competitive pressure at 30%, the PROZAC brand team is likely focused on lifecycle extension and generic transition planning rather than growth initiatives.
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions
Worked on PROZAC at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PROZAC offers limited career growth opportunities given its LOE-approaching lifecycle stage and declining linked job count. Roles available are predominantly defensive, focused on managed decline, generic transition, and stakeholder retention rather than innovation or expansion.